Dual antiplatelet therapy after complex stenting: a decision aid
Part of Heart & circulation clinical trials.
This study tests a tool to help patients with high bleeding and clotting risks decide on the best dual antiplatelet therapy after complex stent placement for a heart attack. Doctors and patients will use the decision aid together to find the safest treatment plan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are hospitalized in the coronary care unit at Montreal Heart Institute
- You had a heart attack and received one or more stents during this hospital stay
- Your doctors have determined you have both high bleeding risk and high clotting risk, and both risks are equally important for your care
- You are not taking blood thinners (like warfarin or apixaban)
- You do not need heart surgery during this hospital stay
- You have never had a stent clot after it was placed
- You do not have a clotting disorder like antiphospholipid syndrome
- You can take part in shared decisions about your treatment and understand English or French
- You are not already enrolled in another research study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a personalized score (OPT-CAD) can help decide the best time to stop or reduce blood-thinning medication in people who have had a heart attack and a stent placed. It aims to balance preventing future heart issues while lowering the risk of bleeding.
This trial studies whether changing the timing and type of blood-thinner tablets after a heart stent is as safe and effective as continuing the same plan. It may help some people by simplifying treatment while preventing dangerous clotting after a coronary procedure.
This Phase 4 study tests a way to measure blood flow in heart arteries to help doctors choose the best stent plan. It may help improve safety and effectiveness for people having elective heart stent procedures for stable angina or certain heart attacks.
This trial tests a shorter course of dual antiplatelet therapy (aspirin plus ticagrelor) after stent placement, switching early to just ticagrelor alone. It aims to see if this approach can safely reduce bleeding risks while still protecting against heart problems in people with stable coronary artery disease.
This trial tests an algorithm (computer-guided plan) to choose the best “dual antiplatelet therapy” (two blood-thinning medicines) after a coronary stent. It aims to improve outcomes after the procedure while reducing avoidable problems from the medicines.
This trial studies ways to reduce bleeding in people after a stent procedure (PCI) who have been taking two anti-platelet medicines (aspirin plus prasugrel or ticagrelor) for a set amount of time. It may help find a safer plan for preventing blood clots while lowering bleeding risk.
Hear when a new Acute Coronary Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.